Skip to content

OrbiMed Capital GP VII LLC, 10% owner at Enliven Therapeutics, sold ELVN on Jun 15, 2026

Data as of Oct 16

▼ SELL$12.3M272,322 shares at $45.02OrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.
Watch ELVN
Traded
Jun 15, 2026
Disclosed
Jun 17, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

OrbiMed Capital GP VII LLC, 10% owner at Enliven Therapeutics, sold ELVN on Jun 15, 2026TRADEDDISCLOSED
ELVNSimilar stocks (XLV — its sector index fund), rebased to ELVN's price on the disclosure day
ELVN since disclosure
−16.8%
after the sale
Similar stocks (XLV) since disclosure
+17.3%
XLV — its sector index fund

Change in closing price from Jun 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$12.3Mdisclosed Jun 17 · filed 2 days after the trade
  2. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$409Kdisclosed Jun 17 · filed 2 days after the trade
  3. ▼ SELLOrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.$409Kdisclosed Jun 17 · filed 2 days after the trade
  4. ▼ SELLOrbimed Advisors LLC 10% ownerELVN Enliven Therapeutics, Inc.$409Kdisclosed Jun 17 · filed 2 days after the trade
  5. ▼ SELLOrbimed Advisors LLC 10% ownerELVN Enliven Therapeutics, Inc.$12.3Mdisclosed Jun 17 · filed 2 days after the trade

See every trade on ELVN →